Gianpiero Locatelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Gianpiero Locatelli has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Alfredo Siani
Department of Diagnostic and Interventional Neuroradiology, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications - Daniele Giuseppe Romano
Department of Diagnostic and Interventional Neuroradiology, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications - Gianmarco Flora
Department of Diagnostic and Interventional Neuroradiology, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications - Giulia Frauenfelder
Department of Diagnostic and Interventional Neuroradiology, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications - Maria Di Gregorio
Department of Neurology and Stroke, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications - Raffaele Tortora
Department of Diagnostic and Interventional Neuroradiology, Ospedali Riuniti San Giovanni di Dio e Ruggi d’Aragona, Salerno, Italy
2 shared publications
Latest Publications
- 26 July 2025
- Published by Springer Nature in Neuroradiology
- Vol. 67 (9) , 2519-2526
Pegasus stent as a rescue therapy in large vessel occlusions with underlying intracranial atherosclerosis: a retrospective Single-Center experience
Purpose Large vessel occlusions (LVOs) due to underlying intracranial atherosclerotic disease (ICAD) are associated with higher rates of mechanical thrombectomy (MT) failure and worse clinical outcomes. The pEGASUS-HPC stent is a novel low-profile device with a hydrophilic polymer coating designed to reduce thrombogenicity. Evidence regarding its use in ICAD-related LVOs is currently limited. Methods We conducted a retrospective single-center study to evaluate the safety and efficacy of the pEGASUS-HPC stent as a rescue treatment following MT failure in ICAD-related LVOs. Results From December 2022 to December 2024 among 393 thrombectomies performed, 25 patients met the inclusion criteria. The mean age was 66 years (53–90) and 18/25 (72%) were men. The anterior circulation was involved in most cases (17/25, 68%). Median baseline NIHSS was 8 and ASPECTS was 9. Rescue stenting was performed due to persistent occlusion (28%), residual stenosis (56%), or early reocclusion (16%). Final TICI 2b–3 recanalization was achieved in 92% of cases. Pre-stenting angioplasty was performed in 32% and post-stenting in 16% of cases. Periprocedural complications occurred in 16% of patients. Median NIHSS at 24 h was 5 and the median ASPECTS was 8. At 24 h, only 1/25 patients demonstrate in-stent thrombosis. Long-term follow-up (6 months) was available for 76% of patients; stent patency was maintained in all, and 84% achieved a favorable outcome (mRS < 2 at 90 days). Conclusion Rescue stenting with the pEGASUS-HPC stent in selected cases of ICAD-related LVO appears to be a feasible and effective treatment option after MT failure, with high recanalization rates, favorable clinical outcomes, and acceptable complication rates.
- 26 July 2025
- Published by Springer Nature in Neuroradiology
- Vol. 67 (9) , 2519-2526
Pegasus stent as a rescue therapy in large vessel occlusions with underlying intracranial atherosclerosis: a retrospective Single-Center experience
Purpose Large vessel occlusions (LVOs) due to underlying intracranial atherosclerotic disease (ICAD) are associated with higher rates of mechanical thrombectomy (MT) failure and worse clinical outcomes. The pEGASUS-HPC stent is a novel low-profile device with a hydrophilic polymer coating designed to reduce thrombogenicity. Evidence regarding its use in ICAD-related LVOs is currently limited. Methods We conducted a retrospective single-center study to evaluate the safety and efficacy of the pEGASUS-HPC stent as a rescue treatment following MT failure in ICAD-related LVOs. Results From December 2022 to December 2024 among 393 thrombectomies performed, 25 patients met the inclusion criteria. The mean age was 66 years (53–90) and 18/25 (72%) were men. The anterior circulation was involved in most cases (17/25, 68%). Median baseline NIHSS was 8 and ASPECTS was 9. Rescue stenting was performed due to persistent occlusion (28%), residual stenosis (56%), or early reocclusion (16%). Final TICI 2b–3 recanalization was achieved in 92% of cases. Pre-stenting angioplasty was performed in 32% and post-stenting in 16% of cases. Periprocedural complications occurred in 16% of patients. Median NIHSS at 24 h was 5 and the median ASPECTS was 8. At 24 h, only 1/25 patients demonstrate in-stent thrombosis. Long-term follow-up (6 months) was available for 76% of patients; stent patency was maintained in all, and 84% achieved a favorable outcome (mRS < 2 at 90 days). Conclusion Rescue stenting with the pEGASUS-HPC stent in selected cases of ICAD-related LVO appears to be a feasible and effective treatment option after MT failure, with high recanalization rates, favorable clinical outcomes, and acceptable complication rates.
- Open Access
- 9 July 2025
- Published by MDPI AG in Preprints.org
pEGASUS-HPC in the Management of Intracranial Atherosclerotic Stenosis: A Retrospective Single- Center Experience
Intracranial atherosclerotic stenosis (ICAS) is a challenging cause of acute large vessel occlusion (LVO), and elective treatment when refractory to medical therapy remains controversial. The pEGASUS HPC is a novel, low-profile, hydrophilic-coated stent designed to reduce thrombogenicity. We retrospectively evaluated its safety and efficacy in both rescue and elective settings. Between December 2022 and December 2024, 40 consecutive patients were treated at our center. Twenty-seven underwent rescue stenting for ICAS-related LVO after ≥3 failed thrombectomy passes or early re-occlusion. Thirteen received elective stenting for symptomatic ICAS meeting WEAVE on-label criteria. Technical success, 24-hour and long-term patency, hemorrhagic complications, and 90-day outcomes (mRS) were assessed. Technical success (final TICI 2b–3) was achieved in 93% of rescue and 100% of elective cases. In the rescue group, symptomatic and asymptomatic hemorrhage occurred in 19% and 22% of patients, with 96% 24-hour and 95% long-term patency; 86% achieved mRS <2 at 90 days. In the elective group, 8% experienced both symptomatic and asymptomatic hemorrhage, with 100% 24-hour and 90% long-term patency; 90% achieved mRS <2. These findings suggest that pEGASUS HPC stenting is feasible and safe in both settings. Prospective trials are needed to confirm its role and refine antiplatelet regimens.
- 9 July 2025
- Published by MDPI AG in Preprints.org
Open AccesspEGASUS-HPC in the Management of Intracranial Atherosclerotic Stenosis: A Retrospective Single- Center Experience
Intracranial atherosclerotic stenosis (ICAS) is a challenging cause of acute large vessel occlusion (LVO), and elective treatment when refractory to medical therapy remains controversial. The pEGASUS HPC is a novel, low-profile, hydrophilic-coated stent designed to reduce thrombogenicity. We retrospectively evaluated its safety and efficacy in both rescue and elective settings. Between December 2022 and December 2024, 40 consecutive patients were treated at our center. Twenty-seven underwent rescue stenting for ICAS-related LVO after ≥3 failed thrombectomy passes or early re-occlusion. Thirteen received elective stenting for symptomatic ICAS meeting WEAVE on-label criteria. Technical success, 24-hour and long-term patency, hemorrhagic complications, and 90-day outcomes (mRS) were assessed. Technical success (final TICI 2b–3) was achieved in 93% of rescue and 100% of elective cases. In the rescue group, symptomatic and asymptomatic hemorrhage occurred in 19% and 22% of patients, with 96% 24-hour and 95% long-term patency; 86% achieved mRS <2 at 90 days. In the elective group, 8% experienced both symptomatic and asymptomatic hemorrhage, with 100% 24-hour and 90% long-term patency; 90% achieved mRS <2. These findings suggest that pEGASUS HPC stenting is feasible and safe in both settings. Prospective trials are needed to confirm its role and refine antiplatelet regimens.